SEC Form 4 · accession 0001209191-18-060160
CRESCENT BIOPHARMA, INC. · CBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Thomas Jackson
Director
Period of report
Nov 27, 2018
Accepted (ET)
Nov 28, 2018 · 7:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001253689
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $11.52 | Nov 27, 2018 | A | 22,000 | A | — | Nov 26, 2028 | Common Stock | 22,000 | 22,000 | D |
Explanation of responses
- F1This option grant was made pursuant to the issuer's non-employee director compensation policy. The shares underlying this option vest in three equal installments on November 27, 2019, 2020 and 2021, subject to the reporting person's continuous service with the issuer at each vesting date.